Dr. Gary C. Doolittle, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 350
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KS license 04-21121
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- University of Kansas Health System Olathe Hospital Olathe, KS
- Miami County Medical Center Paola, KS
Medical groups
- University of Kansas Hospital Authority (250 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 350
- Services billed
- 1,381
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 485 | 207 |
| Established patient office or other outpatient visit, 20-29 minutes | 101 | 73 |
| Established patient office or other outpatient visit, 40-54 minutes | 87 | 59 |
| New patient office or other outpatient visit, 60-74 minutes | 80 | 80 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | 19 |
| New patient office or other outpatient visit, 45-59 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Westwood, KS | 62 |
| Prednisone Other prescribers in Westwood, KS | 57 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Westwood, KS | 55 |
| Hydrocortisone Other prescribers in Westwood, KS | 37 |
| Erivedge (vismodegib) | 36 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Westwood, KS | 34 |
| Gabapentin Other prescribers in Westwood, KS | 33 |
| Mekinist (trametinib dimethyl sulfoxide) | 32 |
| Citalopram Hbr (citalopram hydrobromide) Other prescribers in Westwood, KS | 29 |
| Tafinlar (dabrafenib mesylate) | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $72.46 in total to this clinician.
| Caris Mpi, Inc. | $62.95 |
|---|---|
| Array Biopharma Inc | $9.51 |
| Food and Beverage | $72.46 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $393,214 in research payments for these studies, mostly to the institutions running them.
- Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM)
Immunocore Limited - NCT05361174
Iovance Biotherapeutics, Inc. - A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916 - Study name not reported
Iovance Biotherapeutics, Inc. - A phase 3 randomized doubleblind study of encorafenib and binimetinib plus pembrolizumab versus placebo plus pembrolizumab in participants with braf V600EK mutationpositive metastatic or unresectable locally advanced …
Pfizer Inc. - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [RELAtivity-098]
E.r. Squibb & Sons, L.l.c. - CGME751A12101
Hexal AG
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.